Skip to main content
. Author manuscript; available in PMC: 2019 Jul 13.
Published in final edited form as: J Invest Dermatol. 2018 Mar 6;138(8):1862–1870. doi: 10.1016/j.jid.2018.02.023

Figure 2. Changes in soluble nucleotide-converting activities in PXE patients and Abcc6−/− mice.

Figure 2.

The activities of key soluble enzymes, (a, f) NTPDase1/CD39 (ADPase), (b, g) ecto-5′-nucleotidase/CD73, (c, h) alkaline phosphatase (AP), (d, i) adenylate kinase (AK), and (e, j) nucleotide pyrophosphatase phosphodiesterase (NPP) were determined in (a–e) the serum of healthy control individuals and PXE patients and in (f–j) Abcc6−/− and WT mice. Data represent the mean ± standard error of the mean of the indicated number of serum samples. #P < 0.05; ##P < 0.01. CTRL, control; IU, international unit; nM/mL/hr, nano molar/milliliter/hour; PXE, pseudoxanthoma elasticum.